Enveric Biosciences (ENVB) Competitors $0.76 -0.03 (-3.68%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.75 -0.01 (-1.33%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENVB vs. IBIO, CMMB, ATHA, ABP, PALI, LEXX, NXTC, DWTX, TRAW, and ATNFShould you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include iBio (IBIO), Chemomab Therapeutics (CMMB), Athira Pharma (ATHA), Abpro (ABP), Palisade Bio (PALI), Lexaria Bioscience (LEXX), NextCure (NXTC), Dogwood Therapeutics (DWTX), Traws Pharma (TRAW), and 180 Life Sciences (ATNF). These companies are all part of the "pharmaceutical products" industry. Enveric Biosciences vs. Its Competitors iBio Chemomab Therapeutics Athira Pharma Abpro Palisade Bio Lexaria Bioscience NextCure Dogwood Therapeutics Traws Pharma 180 Life Sciences Enveric Biosciences (NASDAQ:ENVB) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Which has better earnings & valuation, ENVB or IBIO? Enveric Biosciences has higher earnings, but lower revenue than iBio. iBio is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnveric BiosciencesN/AN/A-$9.57M-$38.38-0.02iBio$400K43.04-$24.91M-$1.74-0.49 Do analysts recommend ENVB or IBIO? Enveric Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 1,217.35%. iBio has a consensus target price of $3.50, indicating a potential upside of 311.76%. Given Enveric Biosciences' higher probable upside, research analysts plainly believe Enveric Biosciences is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ENVB or IBIO more profitable? iBio's return on equity of -73.15% beat Enveric Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Enveric BiosciencesN/A -341.48% -240.71% iBio N/A -73.15%-45.51% Does the media favor ENVB or IBIO? In the previous week, iBio had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 4 mentions for iBio and 3 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 0.62 beat iBio's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, ENVB or IBIO? Enveric Biosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ENVB or IBIO? 13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 1.1% of Enveric Biosciences shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryiBio beats Enveric Biosciences on 9 of the 14 factors compared between the two stocks. Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENVB vs. The Competition Export to ExcelMetricEnveric BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.90M$3.40B$6.10B$10.50BDividend YieldN/A2.29%5.73%4.81%P/E Ratio-0.0222.4484.5227.09Price / SalesN/A427.40585.94210.58Price / CashN/A46.5937.1661.22Price / Book0.3210.4112.246.52Net Income-$9.57M-$52.47M$3.32B$276.75M7 Day Performance21.46%2.32%1.25%2.00%1 Month Performance20.49%11.14%6.28%2.26%1 Year Performance-88.68%11.15%59.92%35.58% Enveric Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENVBEnveric Biosciences2.6145 of 5 stars$0.76-3.7%$10.00+1,217.3%-88.5%$4.90MN/A-0.0220News CoverageIBIOiBio2.0694 of 5 stars$0.85+0.1%$5.00+487.5%-70.2%$16.71M$400K-0.49100News CoverageAnalyst ForecastCMMBChemomab Therapeutics2.4114 of 5 stars$3.18+10.9%$26.50+732.5%-35.2%$16.46MN/A-1.3520High Trading VolumeATHAAthira Pharma1.8058 of 5 stars$4.16-3.8%$4.00-3.7%-19.1%$16.37MN/A-0.2740News CoverageABPAbpro2.7102 of 5 stars$0.20+2.1%$4.00+1,886.1%N/A$16.15M$180K0.0015Short Interest ↑Gap UpPALIPalisade Bio2.4183 of 5 stars$1.77-7.3%$12.00+579.9%-51.3%$16.10M$250K-0.4310Short Interest ↑LEXXLexaria Bioscience2.3579 of 5 stars$0.82-2.4%$4.00+387.8%-70.6%$16.04M$460K-1.227Short Interest ↑NXTCNextCure4.505 of 5 stars$5.95-0.9%$25.50+328.6%-31.4%$15.92MN/A-0.2390News CoverageShort Interest ↓DWTXDogwood Therapeutics1.6002 of 5 stars$6.95+3.9%$12.00+72.6%+43.6%$15.87MN/A-0.375Short Interest ↑TRAWTraws Pharma0.842 of 5 stars$2.21-1.6%N/A-39.1%$15.58M$2.90M0.0217ATNF180 Life SciencesN/A$2.55+0.8%N/A-61.4%$15.40MN/A-0.177 Related Companies and Tools Related Companies IBIO Alternatives CMMB Alternatives ATHA Alternatives ABP Alternatives PALI Alternatives LEXX Alternatives NXTC Alternatives DWTX Alternatives TRAW Alternatives ATNF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENVB) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe Truth about AI Stocks’ Money MachineBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
